Pre-Descemet Corneal Dystrophy: Disease Characteristics Report

Scope note. “Pre-Descemet corneal dystrophy” (PDCD) is not one genetically uniform disorder. The 2024 International Committee for Classification of Corneal Dystrophies (IC3D) separates poorly defined, usually sporadic PDCD/cornea farinata-like disease (category 4) from punctiform and polychromatic pre-Descemet corneal dystrophy (PPPCD), a genetically supported autosomal-dominant disorder caused by PRDX3 variants (category 1). Similar deposits can also occur as a manifestation of STS deficiency/X-linked ichthyosis. These entities should not be merged without qualification in a knowledge base. (weiss2024ic3dclassificationof pages 48-49, weiss2024ic3dclassificationof pages 11-12)

Table: This table contrasts the main evidence-supported forms of pre-Descemet corneal disease: poorly defined isolated PDCD, PRDX3-associated PPPCD, and STS/X-linked ichthyosis-associated pre-Descemet opacities. It summarizes what is established, what is inferred, and where major evidence gaps remain.

1. Disease information

PDCD denotes bilateral, generally noninflammatory deposits in the deep corneal stroma immediately anterior to Descemet membrane. The classic appearance is numerous fine, gray, polymorphic opacities; PPPCD has larger punctiform opacities with a distinctive multicolored or polychromatic appearance. Vision is usually preserved. IC3D describes isolated PDCD as neither a well-defined hereditary dystrophy nor an unequivocal degeneration, whereas PRDX3-associated PPPCD now meets category-1 criteria. (weiss2024ic3dclassificationof pages 48-49, weiss2024ic3dclassificationof pages 11-12)

Names and synonyms: pre-Descemet corneal dystrophy; pre-Descemet’s membrane corneal dystrophy; deep filiform dystrophy; deep punctiform dystrophy; cornea farinata (historically overlapping, but now better regarded as a degeneration); punctiform and polychromatic pre-Descemet corneal dystrophy; posterior polychromatic corneal dystrophy. (weiss2024ic3dclassificationof pages 48-49)

Identifiers: no confidently validated disease-specific OMIM, Orphanet, MONDO, MeSH, ICD-10, or ICD-11 identifier was established in the retrieved authoritative literature. A knowledge base should therefore retain the label as an IC3D entity and avoid assigning an unverified MONDO ID. Generic coding may fall under corneal dystrophy or corneal opacity, but that is not disease-specific.

The evidence is aggregated disease-level literature—IC3D expert classification, family studies, and small case series—not individual EHR data. The core sources are IC3D Edition 3, published February 2024 (DOI), and the family/genetic study published April 2020 (DOI). PMIDs were not exposed in the retrieved records and should be verified directly in PubMed before database deposition. (barrio2020punctiformandpolychromatic pages 1-8, weiss2024ic3dclassificationof pages 48-49)

2. Etiology and risk/protective factors

Genetic causes

• PPPCD: heterozygous PRDX3 NM_006793.4:c.568G>C, p.(Asp190His) is the principal reported causal variant. It segregated with disease and was found in four of five evaluated families. Autosomal-dominant transmission is supported. (barrio2020punctiformandpolychromatic pages 17-21, barrio2020punctiformandpolychromatic pages 26-30)
• A rare intronic PDZD8 c.872+10A>T variant segregated in three of five families, but PRDX3 was favored as the causal gene. Possible locus heterogeneity remains unresolved. (barrio2020punctiformandpolychromatic pages 1-8, barrio2020punctiformandpolychromatic pages 17-21)
• Isolated nonpolychromatic PDCD: no locus or causal gene is established; modern series are often sporadic. (weiss2024ic3dclassificationof pages 48-49, alafaleq2020multimodalimagingof pages 1-2)
• Syndromic pre-Descemet opacities: complete deletion of STS was demonstrated in a man with X-linked ichthyosis. This is better annotated as a secondary ocular manifestation of STS deficiency than as PRDX3-associated PPPCD. (shi2017invivoconfocal pages 1-2, shi2017invivoconfocal pages 2-4)

Family history is the principal recognized risk indicator for PPPCD. Cases in the genetic series ranged from 8 to 79 years, showing that detectable disease may span much of life. Geographic clustering among Spanish/Spanish-ancestry and Brazilian families was observed, but the sample is too small to establish a founder effect or population-specific risk. (barrio2020punctiformandpolychromatic pages 17-21, barrio2020punctiformandpolychromatic pages 12-17)

Environmental, lifestyle, infectious, and protective factors

No reproducible toxin, diet, smoking, alcohol, occupational, infectious, or lifestyle cause has been demonstrated. No protective allele, diet, medication, or behavioral intervention is known. Age may affect detectability—classic PDCD is usually recognized after age 30—but PPPCD has been seen by age 3, so age is not a causal exposure. No validated gene–environment interaction exists. (weiss2024ic3dclassificationof pages 48-49)

A report proposing vaccine/surgical stimulation in a person with an ARSG variant is insufficient to establish causation and should not be treated as a recognized PDCD risk factor.

3. Phenotypes

PPPCD is typically mild, bilateral, asymptomatic, and nonprogressive or only mildly progressive. Other PDCD/cornea-farinata-like forms may progress slowly. Onset is commonly recognized in adulthood, but childhood PPPCD is documented. No reliable phenotype frequencies beyond “usually” or “typically” are available because published cohorts are extremely small. (weiss2024ic3dclassificationof pages 48-49, barrio2020punctiformandpolychromatic pages 1-8)

No validated EQ-5D, SF-36, PROMIS, or vision-related quality-of-life study exists. Since corrected acuity is generally normal, everyday functional impact is expected to be minimal, although glare or diagnostic anxiety may matter in individual patients. This is clinical inference rather than measured evidence.

4. Genetic and molecular information

PRDX3 encodes mitochondrial peroxiredoxin-3, an antioxidant peroxidase that regulates mitochondrial reactive oxygen species. The recurrent p.Asp190His substitution was novel in the 2020 study, predicted damaging, and had a CADD score of 31. The retrieved record did not provide a defensible ClinVar classification or current gnomAD allele frequency; therefore “pathogenic” should be used only in the disease-association sense supported by segregation and IC3D category 1, not asserted as a current ClinVar/ACMG record without database verification. (barrio2020punctiformandpolychromatic pages 17-21, barrio2020punctiformandpolychromatic pages 12-17)

The variant is germline, heterozygous, and missense. A dominant-negative versus gain-of-function versus haploinsufficiency mechanism has not been experimentally established. No modifier gene, protective allele, chromosomal rearrangement, somatic mutation, methylation signature, histone change, or other disease-specific epigenetic mechanism is known. The PDZD8 intronic allele remains a candidate rather than a confirmed independent cause. (barrio2020punctiformandpolychromatic pages 1-8, barrio2020punctiformandpolychromatic pages 17-21)

For STS-associated disease, the reported lesion was a germline X-chromosomal deletion encompassing all ten exons and flanking sequence. In the reported male it produced the expected X-linked hemizygous deficiency. (shi2017invivoconfocal pages 1-2, shi2017invivoconfocal pages 2-4)

5. Environmental information

PDCD/PPPCD is not infectious and is not linked to pollution, radiation, smoking, diet, exercise, alcohol, or occupational exposure. Important acquired mimics include crystalline keratopathy and occupational corneal deposits such as argyrosis; these are differential diagnoses, not proven triggers of inherited PPPCD. No environmental prevention strategy is supported.

6. Mechanism and pathophysiology

PRDX3-associated PPPCD

A biologically plausible chain is:

germline PRDX3 p.Asp190His → altered mitochondrial peroxide handling in corneal keratocytes → oxidative/proteostatic stress → intracellular and extracellular deposit formation, greatest in posterior stroma → punctiform polychromatic slit-lamp opacities.

The first step—gene association—is strong; the downstream oxidative/deposition chain is plausible but not directly demonstrated by corneal transcriptomics, proteomics, metabolomics, or functional editing studies. (barrio2020punctiformandpolychromatic pages 17-21, weiss2024ic3dclassificationof pages 11-12)

Sporadic/classic PDCD

IVCM and ultrastructure support a keratocyte-centered degenerative process. Enlarged posterior keratocytes contain membrane-bound vacuoles with electron-dense, lipofuscin-like material; extracellular particles occur throughout the stroma, with maximal damage anterior to Descemet membrane. Epithelium and endothelium are largely spared. (alafaleq2020multimodalimagingof pages 1-2, alafaleq2020multimodalimagingof pages 6-9, alafaleq2020multimodalimagingof pages 4-6)

The 2020 multimodal study’s abstract concluded that findings were “in favor of a degenerative process affecting corneal keratocytes with no epithelial or endothelial involvement.” It also reported that imaging “reveals that the disorder affects the whole stroma.” (DOI, September 2020). (alafaleq2020multimodalimagingof pages 1-2)

STS-associated mechanism

A proposed chain is:

STS deletion → steroid sulfatase deficiency → cholesterol-sulfate accumulation → lysosomal dysfunction/lipid retention in keratocytes → intracellular hyperreflective particles and posterior stromal opacity.

This mechanism is supported by biochemical plausibility and one genetically confirmed clinical case, not by direct human corneal metabolomics. (shi2017invivoconfocal pages 4-5, shi2017invivoconfocal pages 2-4)

Suggested ontology terms: corneal stromal keratocyte (CL term should be curator-verified); corneal stroma and posterior corneal stroma (UBERON); mitochondrion (GO:0005739); lysosome (GO:0005764); response to oxidative stress (GO:0006979); reactive oxygen species metabolic process (GO:0072593); lipid storage/lysosomal organization as provisional biological-process annotations. No immune, inflammatory, ischemic, necrotic, or fibrotic mechanism is established.

No disease-specific bulk/single-cell RNA-seq, spatial transcriptomics, proteomics, metabolomics, lipidomics, multi-omics integration, CRISPR screen, or organoid study was found.

7. Anatomical structures affected

The disease is restricted predominantly to the cornea, especially the deep/posterior stroma immediately anterior to Descemet membrane. Imaging shows lesser deposits and activated keratocytes across anterior and middle stroma as well. Corneal epithelial thickness, Descemet membrane, endothelium, and central corneal thickness are generally normal. (alafaleq2020multimodalimagingof pages 2-4, alafaleq2020multimodalimagingof pages 6-9)

The target cell is the corneal stromal keratocyte. Relevant compartments include mitochondria for PRDX3 biology and lysosomal/vacuolar compartments for lipofuscin-like storage. Disease is typically bilateral and broadly distributed, often limbus-to-limbus, although one STS case retained a 2–3-mm clear perilimbal zone. (shi2017invivoconfocal pages 1-2, alafaleq2020multimodalimagingof pages 2-4)

Suggested anatomy annotations are cornea (UBERON:0000964), corneal stroma, Descemet membrane as an adjacency landmark, and bilateral eye involvement. No established secondary-organ involvement exists in isolated PPPCD; skin involvement belongs to syndromic STS deficiency. IC3D notes a report of crystals under the lens capsule, leaving open whether rare PPPCD may occasionally be systemic. (weiss2024ic3dclassificationof pages 11-12)

8. Temporal development

Classic PDCD is most often recognized after age 30 and develops insidiously. PPPCD can be detected in early childhood and has been documented across ages 3–79. In the 2020 family cohort, affected individuals were 8–79 years old, with mean age 42.9 years. (weiss2024ic3dclassificationof pages 48-49, barrio2020punctiformandpolychromatic pages 12-17)

There is no validated staging system. A practical descriptive sequence is: subclinical deposits detectable by IVCM/OCT; visible punctiform posterior stromal deposits; stable or mildly increasing deposit burden. End-stage corneal decompensation is not characteristic. One STS-associated case remained unchanged at one year. (weiss2024ic3dclassificationof pages 48-49, shi2017invivoconfocal pages 1-2)

The condition is chronic/lifelong once present. Spontaneous remission, relapsing-remitting behavior, critical treatment windows, and treatment-induced remission have not been documented.

9. Inheritance and population

PPPCD follows autosomal-dominant inheritance. Penetrance appears substantial in reported pedigrees but has not been quantified; age-dependent ascertainment is possible. Expressivity is variable in deposit burden, age of recognition, and occasional glare, but visual function is usually preserved. Anticipation, germline mosaicism, consanguinity effects, carrier frequency, and sex bias are unknown. (barrio2020punctiformandpolychromatic pages 1-8, weiss2024ic3dclassificationof pages 48-49)

Only about ten families had been reported before the 2020 study. That study evaluated 21 relatives from three additional families, including 12 affected individuals. These counts demonstrate extreme rarity but cannot yield prevalence or incidence. No population-based rate per 100,000 is available. (barrio2020punctiformandpolychromatic pages 1-8)

Spanish/Spanish-ancestry and Brazilian clustering is reported, but founder status has not been established. Both sexes can be affected in autosomal-dominant PPPCD. The male predominance in one four-patient sporadic imaging series cannot establish a sex ratio. (barrio2020punctiformandpolychromatic pages 17-21, alafaleq2020multimodalimagingof pages 1-2)

10. Diagnostics

Clinical and imaging approach

1. Slit-lamp biomicroscopy: identify bilateral, fine gray or polychromatic punctiform deposits in posterior stroma immediately anterior to Descemet membrane.
2. Anterior-segment OCT: look for hyperreflective particles/line anterior to Descemet membrane; isolated PDCD may also show a thinner line below Bowman layer and particles through the stroma.
3. In-vivo confocal microscopy: demonstrate hyperreflective intracellular inclusions in enlarged posterior keratocytes and extracellular stromal deposits; assess preservation of epithelium and endothelium.
4. Scheimpflug densitometry/specular microscopy: supportive but not independently diagnostic.
5. Visual acuity, refraction, pachymetry, and endothelial cell density: document preserved function and exclude endothelial disease. (barrio2020punctiformandpolychromatic pages 26-30, shi2017invivoconfocal pages 1-2, alafaleq2020multimodalimagingof pages 2-4)

In the STS-associated case, corrected acuity reached 20/20 in both eyes and endothelial densities were 3,347 and 3,095 cells/mm². IVCM localized 2.0–3.4-µm particles within posterior keratocytes at 321–494 µm depth. (shi2017invivoconfocal pages 1-2)

Genetic testing

For a convincing polychromatic familial phenotype, sequence PRDX3, preferably through an inherited corneal-dystrophy panel with deletion/duplication analysis and segregation testing. Targeted testing for c.568G>C is efficient in a known family. WES/WGS is appropriate when PRDX3 testing is negative, the phenotype is atypical, or syndromic findings suggest another diagnosis. In males with ichthyosis, test STS by copy-number analysis plus sequencing. CMA may detect a larger Xp22.3 deletion. Karyotyping, FISH, mitochondrial DNA testing, and repeat-expansion assays have no routine role unless another clinical indication exists. (barrio2020punctiformandpolychromatic pages 1-8, shi2017invivoconfocal pages 2-4)

Differential diagnosis

Important alternatives are cornea farinata; fleck corneal dystrophy; central cloudy dystrophy of François; posterior amorphous corneal dystrophy; Fuchs endothelial corneal dystrophy/cornea guttata; posterior polymorphous corneal dystrophy; crystalline infectious keratopathy; Schnyder corneal dystrophy; cystinosis; drug/toxin or silver deposits; and pre-Descemet opacities secondary to X-linked ichthyosis. Normal endothelium, lack of edema/inflammation, posterior stromal keratocyte localization, polychromasia, and PRDX3 segregation favor PPPCD. (alafaleq2020multimodalimagingof pages 6-9)

There are no universally validated numerical diagnostic criteria. Asymptomatic relatives in a PRDX3-positive family can undergo cascade slit-lamp examination and targeted testing. Population or newborn screening is not indicated.

11. Outcome and prognosis

Prognosis is excellent. Most patients remain asymptomatic with preserved corrected acuity, and the disease does not affect survival or life expectancy. No disease-specific mortality, five- or ten-year survival statistic, disability rate, or quality-of-life score exists. (weiss2024ic3dclassificationof pages 48-49, barrio2020punctiformandpolychromatic pages 1-8)

When reduced vision is present, published imaging series attributed it to other conditions such as amblyopia, cataract, or retinal pigment epitheliopathy rather than PDCD. Corneal edema, endothelial failure, recurrent erosions, ulceration, and blindness are not characteristic complications. (alafaleq2020multimodalimagingof pages 6-9)

No validated prognostic biomarker exists. Deposit burden, symptoms, acuity, and serial OCT/IVCM are reasonable monitoring measures, but their predictive value is unproven.

12. Treatment

Standard care is observation and periodic ophthalmic review. Refractive correction treats coincidental ametropia; glare can be managed symptomatically. Genetic counseling is appropriate for PRDX3-positive families and STS-associated disease. A 2025 case report likewise recommended observation/follow-up and noninvasive imaging. (nicoli2025distrofiacornealpredescemética pages 3-5)

No drug, antioxidant, lysosomal therapy, gene therapy, RNA therapy, cell therapy, PTK, keratoplasty, or other surgery has demonstrated disease-specific benefit. Because deposits are deep and visual acuity is generally preserved, PTK is anatomically inappropriate in routine PPPCD. Corneal transplantation would be considered only for exceptional, proven visually significant stromal opacity after exclusion of other causes; no response rate or recurrence estimate exists.

No relevant interventional ClinicalTrials.gov study or disease-specific NCT identifier was found. Generic patents and experimental gene-editing approaches for other corneal dystrophies do not constitute evidence for PDCD treatment. Suggested NCIT concepts are Observation, Genetic Counseling, Visual Acuity Test, Optical Coherence Tomography, and, only if exceptionally indicated, Corneal Transplantation; exact NCIT codes should be terminology-service verified.

13. Prevention

Primary prevention is unavailable for a germline disorder. No vaccine, prophylactic drug, diet, or exposure avoidance prevents PPPCD. Secondary prevention consists of cascade examination/testing in affected families, allowing early diagnosis and avoidance of unnecessary treatment. Tertiary prevention consists of routine monitoring and treatment of unrelated visual problems.

Genetic counseling should explain autosomal-dominant transmission—nominally a 50% variant-transmission probability from a heterozygous parent—while emphasizing that penetrance and severity are not adequately quantified. Prenatal or preimplantation testing is technically possible once a familial pathogenic variant is confirmed but is rarely proportionate for a usually asymptomatic, non–vision-threatening condition. STS families require X-linked counseling. No population screening or public-health intervention is justified.

14. Other species and natural disease

No genetically confirmed natural PRDX3-associated PDCD has been established in another species. A 2022 canine report described bilateral, noninflammatory posterior stromal opacities with hyperreflective deposits within keratocytes and increasing numbers of enlarged deposit-containing keratocytes toward the posterior stroma. The authors judged this “reminiscent of pre-Descemet corneal dystrophy” in humans, but no orthologous mutation was demonstrated; it is therefore a comparative phenocopy, not a validated natural model. Relevant taxonomy is domestic dog, Canis lupus familiaris (NCBI Taxon 9615). Breed/VBO assignment was not established in the retrieved evidence.

There is no zoonotic or transmissible potential.

15. Model organisms

No validated PRDX3 knock-in mouse, rat, zebrafish, invertebrate, organoid, iPSC, or corneal-cell model has been shown to reproduce human PPPCD deposits. Likewise, no STS-deficient model has been validated specifically for the corneal phenotype. The canine observation may help define comparative imaging features but cannot establish causality or therapeutic response.

Priority models would include: (1) a heterozygous PRDX3 p.Asp190His knock-in animal; (2) patient-derived keratocytes or iPSC-derived corneal stromal cells; and (3) engineered corneal stromal organoids assessing mitochondrial peroxide handling, keratocyte vacuoles, lipofuscin/lipid deposition, transparency, and biomechanics. These are research recommendations, not currently validated resources.

Recent developments and evidence-quality assessment

The key recent advance is the February 2024 IC3D reclassification: PRDX3-associated PPPCD is now category 1, while isolated nonpolychromatic PDCD remains category 4. IC3D’s abstract states: “Pre-Descemet corneal dystrophies include category 1, autosomal dominant, punctiform and polychromatic pre-Descemet corneal dystrophy (PPPCD) (PRDX3 mutations, chromosome 10)” and notes that it is “typically asymptomatic.” (DOI, February 2024). (weiss2024ic3dclassificationof pages 48-49)

The foundational genetic evidence remains the April 2020 family study: 12 affected people in three newly reported families, recurrence of PRDX3 p.Asp190His in four of five families evaluated across the study, and significantly increased corneal stiffness as the principal measured biomechanical abnormality. Its main limitations are small sample size, concentration in a few ancestries, prediction rather than direct functional proof, and unresolved locus heterogeneity. (barrio2020punctiformandpolychromatic pages 1-8, barrio2020punctiformandpolychromatic pages 17-21)

Overall, evidence is moderate-to-strong for PRDX3 as the cause of PPPCD, moderate for a keratocyte deposition/degeneration mechanism, and very low for epidemiology, quantified natural history, molecular profiling, or treatment efficacy. The most important database-curation safeguard is to keep PRDX3-associated PPPCD, category-4 isolated PDCD/cornea farinata, and STS-associated syndromic deposits as related but distinct assertions.

References

1. (weiss2024ic3dclassificationof pages 48-49): Jayne S. Weiss, Christopher J. Rapuano, Berthold Seitz, Massimo Busin, Tero T. Kivelä, Nacim Bouheraoua, Cecilie Bredrup, Ken K. Nischal, Harshvardhan Chawla, Vincent Borderie, Kenneth R. Kenyon, Eung Kweon Kim, Hans Ulrik Møller, Francis L. Munier, Tim Berger, and Walter Lisch. Ic3d classification of corneal dystrophies—edition 3. Cornea, 43:466-527, Feb 2024. URL: https://doi.org/10.1097/ico.0000000000003420, doi:10.1097/ico.0000000000003420. This article has 119 citations and is from a peer-reviewed journal.

2. (weiss2024ic3dclassificationof pages 11-12): Jayne S. Weiss, Christopher J. Rapuano, Berthold Seitz, Massimo Busin, Tero T. Kivelä, Nacim Bouheraoua, Cecilie Bredrup, Ken K. Nischal, Harshvardhan Chawla, Vincent Borderie, Kenneth R. Kenyon, Eung Kweon Kim, Hans Ulrik Møller, Francis L. Munier, Tim Berger, and Walter Lisch. Ic3d classification of corneal dystrophies—edition 3. Cornea, 43:466-527, Feb 2024. URL: https://doi.org/10.1097/ico.0000000000003420, doi:10.1097/ico.0000000000003420. This article has 119 citations and is from a peer-reviewed journal.

3. (alafaleq2020multimodalimagingof pages 1-2): Munirah Alafaleq, Cristina Georgeon, Kate Grieve, and Vincent M Borderie. Multimodal imaging of pre-descemet corneal dystrophy. European Journal of Ophthalmology, 30:908-916, Sep 2020. URL: https://doi.org/10.1177/1120672119862505, doi:10.1177/1120672119862505. This article has 9 citations and is from a peer-reviewed journal.

4. (alafaleq2020multimodalimagingof pages 4-6): Munirah Alafaleq, Cristina Georgeon, Kate Grieve, and Vincent M Borderie. Multimodal imaging of pre-descemet corneal dystrophy. European Journal of Ophthalmology, 30:908-916, Sep 2020. URL: https://doi.org/10.1177/1120672119862505, doi:10.1177/1120672119862505. This article has 9 citations and is from a peer-reviewed journal.

5. (alafaleq2020multimodalimagingof pages 6-9): Munirah Alafaleq, Cristina Georgeon, Kate Grieve, and Vincent M Borderie. Multimodal imaging of pre-descemet corneal dystrophy. European Journal of Ophthalmology, 30:908-916, Sep 2020. URL: https://doi.org/10.1177/1120672119862505, doi:10.1177/1120672119862505. This article has 9 citations and is from a peer-reviewed journal.

6. (alafaleq2020multimodalimagingof pages 2-4): Munirah Alafaleq, Cristina Georgeon, Kate Grieve, and Vincent M Borderie. Multimodal imaging of pre-descemet corneal dystrophy. European Journal of Ophthalmology, 30:908-916, Sep 2020. URL: https://doi.org/10.1177/1120672119862505, doi:10.1177/1120672119862505. This article has 9 citations and is from a peer-reviewed journal.

7. (barrio2020punctiformandpolychromatic pages 1-8): Jorge L. Alió del Barrio, Doug D. Chung, Olena Al-Shymali, Alice Barrington, Kavya Jatavallabhula, Vinay S. Swamy, Pilar Yébana, Maria Angélica Henríquez-Recine, Ana Boto-de-los-Bueis, Jorge L. Alió, and Anthony J. Aldave. Punctiform and polychromatic pre-descemet corneal dystrophy: clinical evaluation and identification of the genetic basis. American Journal of Ophthalmology, 212:88-97, Apr 2020. URL: https://doi.org/10.1016/j.ajo.2019.11.024, doi:10.1016/j.ajo.2019.11.024. This article has 12 citations and is from a domain leading peer-reviewed journal.

8. (barrio2020punctiformandpolychromatic pages 17-21): Jorge L. Alió del Barrio, Doug D. Chung, Olena Al-Shymali, Alice Barrington, Kavya Jatavallabhula, Vinay S. Swamy, Pilar Yébana, Maria Angélica Henríquez-Recine, Ana Boto-de-los-Bueis, Jorge L. Alió, and Anthony J. Aldave. Punctiform and polychromatic pre-descemet corneal dystrophy: clinical evaluation and identification of the genetic basis. American Journal of Ophthalmology, 212:88-97, Apr 2020. URL: https://doi.org/10.1016/j.ajo.2019.11.024, doi:10.1016/j.ajo.2019.11.024. This article has 12 citations and is from a domain leading peer-reviewed journal.

9. (barrio2020punctiformandpolychromatic pages 26-30): Jorge L. Alió del Barrio, Doug D. Chung, Olena Al-Shymali, Alice Barrington, Kavya Jatavallabhula, Vinay S. Swamy, Pilar Yébana, Maria Angélica Henríquez-Recine, Ana Boto-de-los-Bueis, Jorge L. Alió, and Anthony J. Aldave. Punctiform and polychromatic pre-descemet corneal dystrophy: clinical evaluation and identification of the genetic basis. American Journal of Ophthalmology, 212:88-97, Apr 2020. URL: https://doi.org/10.1016/j.ajo.2019.11.024, doi:10.1016/j.ajo.2019.11.024. This article has 12 citations and is from a domain leading peer-reviewed journal.

10. (barrio2020punctiformandpolychromatic pages 12-17): Jorge L. Alió del Barrio, Doug D. Chung, Olena Al-Shymali, Alice Barrington, Kavya Jatavallabhula, Vinay S. Swamy, Pilar Yébana, Maria Angélica Henríquez-Recine, Ana Boto-de-los-Bueis, Jorge L. Alió, and Anthony J. Aldave. Punctiform and polychromatic pre-descemet corneal dystrophy: clinical evaluation and identification of the genetic basis. American Journal of Ophthalmology, 212:88-97, Apr 2020. URL: https://doi.org/10.1016/j.ajo.2019.11.024, doi:10.1016/j.ajo.2019.11.024. This article has 12 citations and is from a domain leading peer-reviewed journal.

11. (shi2017invivoconfocal pages 4-5): Hui Shi, Xiao-feng Qi, Tao-tao Liu, Qian Hao, Xiao-hong Li, Ling-ling Liang, Yi-miao Wang, and Zhi-hua Cui. In vivo confocal microscopy of pre-descemet corneal dystrophy associated with x-linked ichthyosis: a case report. BMC Ophthalmology, Mar 2017. URL: https://doi.org/10.1186/s12886-017-0423-5, doi:10.1186/s12886-017-0423-5. This article has 18 citations and is from a peer-reviewed journal.

12. (shi2017invivoconfocal pages 1-2): Hui Shi, Xiao-feng Qi, Tao-tao Liu, Qian Hao, Xiao-hong Li, Ling-ling Liang, Yi-miao Wang, and Zhi-hua Cui. In vivo confocal microscopy of pre-descemet corneal dystrophy associated with x-linked ichthyosis: a case report. BMC Ophthalmology, Mar 2017. URL: https://doi.org/10.1186/s12886-017-0423-5, doi:10.1186/s12886-017-0423-5. This article has 18 citations and is from a peer-reviewed journal.

13. (shi2017invivoconfocal pages 2-4): Hui Shi, Xiao-feng Qi, Tao-tao Liu, Qian Hao, Xiao-hong Li, Ling-ling Liang, Yi-miao Wang, and Zhi-hua Cui. In vivo confocal microscopy of pre-descemet corneal dystrophy associated with x-linked ichthyosis: a case report. BMC Ophthalmology, Mar 2017. URL: https://doi.org/10.1186/s12886-017-0423-5, doi:10.1186/s12886-017-0423-5. This article has 18 citations and is from a peer-reviewed journal.

14. (nicoli2025distrofiacornealpredescemética pages 3-5): CM Nicoli and ES López. Distrofia corneal pre-descemética. Unknown journal, 2025.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.